Particular aspects concerning acromegaly amid pandemic
Authors:   “C.I. Parhon“ National Institute of Endocrinology, Bucharest, Romania, CARSOTE Mara ,   “Carol Davila“ University of Medicine and Pharmacy, Bucharest, Romania, SANDRU Florica ,   “Carol Davila“ University of Medicine and Pharmacy, Bucharest, Romania,   Elias Emergency Hospital, Bucharest, Romania, RENTEA Diana Elena ,   “C.I. Parhon“ National Institute of Endocrinology, Bucharest, Romania, ZUGRAVU Stefania ,   “C.I. Parhon“ National Institute of Endocrinology, Bucharest, Romania, MEHEDINTU Claudia ,   “Carol Davila“ University of Medicine and Pharmacy, Bucharest, Romania,   “Nicolae Malaxa“ Clinical Hospital, Bucharest, Romania, DUMITRASCU Anda ,   “C.I. Parhon“ National Institute of Endocrinology, Bucharest, Romania, DUMITRASCU Mihai Cristian ,   “Carol Davila“ University of Medicine and Pharmacy, Bucharest, Romania,   University Emergency Hospital, Bucharest, Romania
Published: April 2022

Acromegaly embraces typical complications of a pituitary tumor as well as GH (growth hormone) and IGF1 (insulin-like growth factor) excess-related cardio-metabolic and oncologic conditions; and associated medical, surgical treatment or even radiotherapy issues. We point out a few particular aspects concerning acromegaly issues amid COVID-19 pandemic. The review includes only full length, English published papers. One of the most important complications of long standing, untreated or un-responsive to therapy acromegaly is related to respiratory and otorhinolaryngology issues like sleep apnea; this becomes an important aspect causing pulmonary complications in patients with active coronavirus infection. In subjects who are not going through a COVID-19 infection, but they had a prior diagnostic of acromegaly, two main aspects of medical and surgical practice were noted: a massive reduction of surgical volume during the first year of pandemic, mostly during peak months of high infection rate in general population and the introduction of tele (digital) health care systems, of different protocols and various platforms mostly depending of medical center, rather than country or even continent related protocols. Associated central adrenal insufficiency requires a particular attention if COVID-19 positive. The data directly targeting the endocrinologists amid pandemic are very limited. ACROCOVID is a 2021 study that was internationally conducted based on a questionnaire that was applied to 84 endocrinologists (67% of them in Europe); 33% of acromegalic individuals had a delay on procedure because of insufficient COVID-19 assays and 54% of them due to inefficient provision for neurosurgery. Secondary diabetes mellitus (with a potential worsening in some patients due to pasireotide LAR) is at high risk for COVID-19 infection; the level of glycated hemoglobin A1c seems a good predictor at onset of infectious disease. Acromegaly might associate osteoporosis; coronavirus infection aggravates bone loss due to oxidative stress, inflammatory status, cytokine release, immobilization, glucocorticoid use. Acromegaly field concerning pandemic changes represents a complex, still ongoing matter involving both patients and multidisciplinary practitioners.